Cystistat (sodium hyaluronate) / China Medical System, Viatris - LARVOL DELTA

Intravesical Instillation of Hyaluronic Acid (Cystistat) for the Treatment of Category III Prostatitis: A Retrospective Study. (PubMed, Neurourol Urodyn) - "Intravesical hyaluronic acid (Cystistat) therapy appears to be clinically effective for CP/CPPS, particularly in pain relief and quality-of-life improvement. Patients with elevated CRP levels and shorter disease duration may benefit more from this treatment. The derived predictive model offers a tool for individualized clinical decision-making. These findings lend indirect support to the "bladder-prostate axis" hypothesis, suggesting that Cystistat may alleviate pelvic pain by restoring bladder mucosal integrity and reducing inflammatory mediator activity. Future prospective randomized controlled trials are needed to validate these findings and further elucidate the underlying mechanisms. Further prospective, large-scale studies are needed to confirm efficacy, especially in OAB-associated subtypes, and refine predictive modeling approaches."

Journal • Retrospective data • Gynecology • Inflammation • Interstitial Cystitis • Musculoskeletal Pain • Pain • CRP

IC/BPS: Real-world Evidence Study on Cystistat (clinicaltrials.gov) - P=N/A | N=74 | Completed | Sponsor: MEDA Pharma GmbH & Co. KG | Active, not recruiting ➔ Completed

HEOR • Real-world evidence • Trial completion • Interstitial Cystitis • Musculoskeletal Pain • Pain

IC/BPS: Real-world Evidence Study on Cystistat (clinicaltrials.gov) - P=N/A | N=74 | Active, not recruiting | Sponsor: MEDA Pharma GmbH & Co. KG | Recruiting ➔ Active, not recruiting

Enrollment closed • HEOR • Real-world • Real-world evidence • Interstitial Cystitis • Musculoskeletal Pain • Pain

Cystoscopic application of PuraStat® in the treatment of radiation-induced haemorrhagic cystitis. (PubMed, Ann R Coll Surg Engl) - "We continue to monitor the effects in the medium and long term. Based on current data, PuraStat® haemostatic agent therapy may be considered for RHC, when traditional treatments are ineffective or infeasible, potentially eliminating the need for more aggressive therapy such as cystectomy."

Journal • Oncology

IC/BPS: Real-world Evidence Study on Cystistat (clinicaltrials.gov) - P=N/A | N=74 | Recruiting | Sponsor: MEDA Pharma GmbH & Co. KG | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2023 ➔ Mar 2025 | Trial primary completion date: Aug 2023 ➔ Jan 2025

Enrollment open • HEOR • Real-world • Real-world evidence • Trial completion date • Trial primary completion date • Interstitial Cystitis • Musculoskeletal Pain • Pain

IC/BPS: Real-world Evidence Study on Cystistat (clinicaltrials.gov) - P=N/A | N=74 | Not yet recruiting | Sponsor: MEDA Pharma GmbH & Co. KG

HEOR • New trial • Real-world evidence • Interstitial Cystitis • Musculoskeletal Pain • Pain

Effect of Glycosaminoglycan Replacement on Markers of Interstitial Cystitis In Vitro. (PubMed, Front Pharmacol) - " The data presented in this study reveal that commercial intravesical formulation support cell viability and migration. In addition, the commercial GAG formulations have a mild anti-inflammatory effect in the in vitro model of interstitial cystitis/bladder pain syndrome."

Journal • Immunology • Inflammation • Interstitial Cystitis • Musculoskeletal Pain • Pain • CXCL8 • ICAM1 • MMP2 • TIMP1 • TNFA

Intravesical sodium hyaluronate for treatment of cystitis & bladder pain in women with pelvic malignancies (ESGO 2019) - "All patients without history of malignancy (4/4) reported some improvement, and of these 75% (3/4) reported significant change. Conclusion Bladder instillation of sodium hyaluronate was effective in reducing the symptoms of radiation cystitis in women treated for gynaecological malignancies."

Clinical